Exact Sciences to participate in December investor conference

On November 26, 2019 Exact Sciences Corp. (Nasdaq: EXAS) reported that company management will be participating in the following investor conference (Press release, Exact Sciences, NOV 26, 2019, View Source [SID1234551683]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Evercore ISI HealthCONx, Boston
Fireside chat on December 4, 2019, at 2:45 p.m. EST
The webcast can be accessed in the investor relations section of Exact Sciences’ website at www.exactsciences.com.

Bristol-Myers Squibb to Hold Investor Webcast to Discuss ASH Highlights

On November 26, 2019 Bristol-Myers Squibb Company (NYSE: BMY) reported that it will hold an investor webcast on Sunday, December 8, 2019 at 8:00 p.m. ET to discuss data presented at the American Society of Hematology (ASH) (Free ASH Whitepaper) meeting, in Orlando (Press release, Bristol-Myers Squibb, NOV 26, 2019, View Source [SID1234551681]). Company executives will provide an overview of data presented and address questions from investors and analysts.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors and the general public are invited to listen to a live webcast of the event at investor.bms.com. Materials related to the event will be available at the same website prior to the event. A replay of the event will be available and can be accessed at investor.bms.com.

Anixa Biosciences Announces Genesis Research to Join Cchek™ Prostate Cancer Study

On November 26, 2019 Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body’s immune system in the fight against cancer, reported the addition of Genesis Research, LLC to the ongoing Cchek prostate cancer detection study (Press release, Anixa Biosciences, NOV 26, 2019, View Source [SID1234551680]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Genesis Research, LLC the research arm of Genesis Healthcare Partners, based in San Diego, CA, joins a large and growing team of collaborators advancing Anixa’s Cchek artificial intelligence driven liquid biopsy technology toward commercialization. Genesis Research will provide patient samples in support of clinical validation of Anixa’s Cchek Prostate Cancer Confirmation test.

Study enrollment will be led by Genesis Research’s Medical Director, Dr. Paul Dato. Dr. Dato commented, "This is an exciting opportunity for research personnel at Genesis Healthcare Partners to collaborate with Anixa and explore the potential of immune cells to detect the presence of Prostate Cancer."

Dr. Franklin Gaylis, Chief Scientific Officer at Genesis Healthcare Partners, has endorsed the collaboration between the two organizations and commented, "Genesis Healthcare Partners has an active research program focused on the early detection of Prostate Cancer. Our collaboration with Anixa provides a great opportunity to explore the potential for developing a liquid biopsy for detecting Prostate Cancer."

Amit Kumar, Ph.D., Chief Executive Officer of Anixa stated, "We are pleased to have Genesis Research join our expanding group of Cchek collaboration partners. Our team of collaborators have been and continue to be instrumental in the development of our early cancer detection technology. We look forward to Genesis Research’s participation as we prepare for commercial launch of the Cchek Prostate Cancer Confirmation test in the coming weeks."

About Cchek
Cchek is an early cancer detection technology, that measures a patient’s immunological response to a malignancy by analyzing immune system cells in peripheral blood. The goal is to utilize the technology to determine a patient’s cancer status from a simple blood draw, eliminating the need for a biopsy, which can be an expensive, painful and invasive procedure. Further, conventional methods using current cancer screening tests often lack accuracy and reliability. Anixa’s orthogonal approach using flow cytometry coupled with artificial intelligence provides an alternative method that offers improved affordability, efficacy and efficiency. To date, Anixa has successfully used Cchek to detect the presence of 20 different cancers including lung, colon, breast and prostate. The robust cancer detection performance of Cchek makes it a platform from which multiple cancer diagnostic tests may be developed. The first such test, a prostate cancer confirmation test, is slated for commercial launch by the end of 2019.

Genesis Research, LLC
Genesis Research is the wholly owned research subsidiary of Genesis Healthcare Partners, San Diego’s largest premier multi-specialty independent private physician practice, dedicated to the diagnosis and treatment of urologic conditions, digestive health issues and many cancers. With 15 offices located throughout San Diego County, Genesis Healthcare Partners’ team of medical professionals provides access to cutting-edge technology and minimally invasive treatments. Additional information is available at www.mygenesishealth.com.

Alpine Immune Sciences to Participate in Fireside Chat at 31st Annual Piper Jaffray Healthcare Conference

On November 26, 2019 Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, reported participation in an analyst-led fireside chat at the 31st Annual Piper Jaffray Healthcare Conference on Tuesday, December 3, 2019 at 3:00 p.m. Eastern Time in New York, NY (Press release, Alpine Immune Sciences, NOV 26, 2019, View Source [SID1234551679]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the fireside chat will be available online in the investor relations section of the company’s website at View Source A replay of the presentation will be available on the company website for 90 days following the webcast.

Granting of the Marketing Authorisation for Ivozall

On November 26, 2019 ORPHELIA Pharma, a French biopharmaceutical company dedicated to the development and marketing of paediatric drugs in the fields of oncology and neurology, reported that the European Commission has granted Ivozall an European Marketing Authorisation (MA) (Press release, ORPHELIA Pharma, NOV 26, 2019, View Source [SID1234551678]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Ivozall is a solution for infusion containing 1 mg/ml of clofarabine and is supplied in 20 ml-vials. Clofarabine is an essential medicine for the treatment of relapsed or refractory Acute Lymphoblastic Leukaemia (ALL) in children. Ivozall will be the first generic form of clofarabine to be authorised under the European centralized procedure.

« This approval is a significant milestone for ORPHELIA Pharma as Ivozall is the first medicine in a series of oncology products we plan to launch. We believe it addresses important pediatric needs and will meaningfully improve children’s care », comments Jeremy Bastid, Chief Development Officer. « We will now focus on launching Ivozall throughout Europe and building relationships with distribution partners to bring Ivozall to patients with ALL ».

« This MA will allow the company to strengthen its product portfolio with this first oncology medicine in which we have great expectations » says Hugues Bienaymé, Founder and General Manager. « We anticipate to make Ivozall available to hospital centres treating ALL patients in some countries from March 2020. Other countries will be handled by ORPHELIA’s distributors, to be selected in the course of 2020 ».

About Acute Lymphoblastic Leukaemia

ALL is a cancer associated with the uncontrolled proliferation of lymphoblasts that invade the bone marrow. The disease progresses rapidly and aggressively and requires immediate treatment. ALL is a rare disease, with around 7,000 people diagnosed each year in Europe. The majority of ALL cases occurs in children. Although rare, ALL is the most common type of childhood cancer. Clofarabine is indicated for the treatment of ALL in paediatric patients who have relapsed or are refractory after receiving at least two prior regimens and where there is no other treatment option anticipated to result in a durable response.